Wedbush Predicts Lower Earnings for Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Wedbush decreased their FY2027 earnings estimates for Apellis Pharmaceuticals in a research note issued on Tuesday, October 14th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.33) per share for the year, down from their previous forecast of $0.12. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ FY2028 earnings at $0.92 EPS.

A number of other equities analysts also recently weighed in on the stock. JPMorgan Chase & Co. increased their price target on shares of Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, August 4th. Cantor Fitzgerald increased their price target on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Bank of America increased their price target on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 16th. Wells Fargo & Company began coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday. They set an “overweight” rating and a $32.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $33.47.

Apellis Pharmaceuticals Stock Up 1.5%

Shares of NASDAQ APLS opened at $24.52 on Thursday. Apellis Pharmaceuticals has a 1 year low of $16.10 and a 1 year high of $35.72. The firm’s 50 day moving average price is $25.38 and its 200 day moving average price is $21.18. The firm has a market cap of $3.10 billion, a P/E ratio of -13.47 and a beta of 0.69. The company has a debt-to-equity ratio of 2.90, a quick ratio of 3.16 and a current ratio of 3.77.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The firm had revenue of $171.39 million for the quarter, compared to analyst estimates of $187.91 million. During the same quarter last year, the business earned ($0.30) earnings per share. Apellis Pharmaceuticals’s revenue was down 10.6% compared to the same quarter last year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 0.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 58,856 shares of the company’s stock valued at $1,019,000 after buying an additional 465 shares during the period. GF Fund Management CO. LTD. boosted its stake in Apellis Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after purchasing an additional 573 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Apellis Pharmaceuticals by 15.6% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock valued at $84,000 after purchasing an additional 655 shares during the period. Parallel Advisors LLC boosted its stake in Apellis Pharmaceuticals by 80.0% during the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after purchasing an additional 855 shares during the period. Finally, Baird Financial Group Inc. boosted its stake in Apellis Pharmaceuticals by 1.6% during the 1st quarter. Baird Financial Group Inc. now owns 55,529 shares of the company’s stock valued at $1,214,000 after purchasing an additional 864 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director A. Sinclair Dunlop sold 31,092 shares of the business’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $23.72, for a total value of $737,502.24. Following the completion of the sale, the director owned 3,837 shares of the company’s stock, valued at approximately $91,013.64. The trade was a 89.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of the business’s stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $25.22, for a total transaction of $126,100.00. Following the completion of the sale, the general counsel directly owned 113,730 shares of the company’s stock, valued at $2,868,270.60. The trade was a 4.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 302,921 shares of company stock valued at $8,210,566 in the last quarter. Company insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).